Fostamatinib (TAVALISSE)
Chronic Immune Thrombocytopenia (ITP)
ApprovedCommercial (Japan)
Key Facts
Indication
Chronic Immune Thrombocytopenia (ITP)
Phase
Approved
Status
Commercial (Japan)
Company
About Nippon Shinyaku
Nippon Shinyaku's mission is to address high-unmet medical needs through pioneering science, particularly in rare diseases. Its key achievement is the development and commercialization of Viltepso (viltolarsen), an exon-skipping therapy for Duchenne muscular dystrophy, establishing its technological credibility. The company's strategy is built on deep R&D in targeted therapeutic areas, a dominant position in the Japanese market, and strategic international expansion, especially in the United States.
View full company profileTherapeutic Areas
Other Chronic Immune Thrombocytopenia (ITP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Fostamatinib (TAK-079 / MND-379) | Mochida Pharmaceutical | Launched |
| Doptelet (avatrombopag) | Swedish Orphan Biovitrum | Marketed / Phase 4 |
| TAVALISSE (fostamatinib) | Rigel Pharmaceuticals | Marketed |